5.7.4. pharmacological management. 5.7.4.1. parasympathomimetics mechanism action parasympathomimetics, see section 5.2.3. sr meta-analysis performed male female patients uab evaluating twelve rcts use subgroups (muscarinic agonists acetylcholinesterase inhibitors) parasympathomimetics . meta-analysis showed small benefit patients (post-procedure) urinary retention increase adverse events, without improvement pvr. however, results sr confounded low number small studies, weak data, high heterogeneity short-term follow up. therefore, based upon available literature, strong evidence-based conclusions drawn role parasympathomimetics effective pharmaceutical treatment uab. 5.7.4.2. alpha-adrenergic blockers one alternative improve bladder emptying micturition reducing outflow resistance patients uab. although lack high quality rcts, evidence exists lowering outflow resistance improves voiding functions bothersome symptoms men uab. single-blind prospective rct investigated 119 patients uab treating cholinergic drug, alpha-adrenergic blocker both. showed significant improvement symptoms well pvr flow rate patients treated combination therapy compared monotherapy . study evaluated effects tadalafil (a pde5 inhibitor) silodosin voiding function male patients non-neurogenic du. propensity score matching, showed improvement qol uds parameters voiding parameters subgroups . overall, clinical rigor required provide evidence‚Äêbased support use class medications treating uab still lacking. 5.7.4.3. prostaglandins prostaglandins involved modulation bladder function. five subtypes, prostaglandins e2 f2a appear predominant stimulating detrusor contractions. cochrane review analysing three rcts using intravesical instillation pge2 pgf2a, suggests reduction postoperative retention catheter removal . however due methodological limitations included trials, use clinical practice remains uncertain. one placebo-controlled trial investigated combination intravesical pge2 bethanechol chloride nineteen patients uab . although showed reduction pvr compared placebo, clinical relevance questioned. overall, efficacy prostaglandin agents treating uab established. 5.7.4.4. drugs previously stated, treatment pde5 inhibitors (such tadalafil) showed improvement qol uds parameters voiding parameters male patients uab . information pde5s, please see section 5.2.5. summary evidenceleevidence effect parasympathomimetics clinical urodynamic parameters uab lacking. possible serious adverse effects considered administration.4there limited evidence effectiveness alpha-adrenergic blockers men uab.4the efficacy prostaglandin agents treating uab established.4 recommendationsstrength ratingdo routinely recommend parasympathomimetics treatment men underactive bladder.strongoffer alpha-adrenergic blockers more-invasive techniques.weak